 Connection
Thomas Flaig to Mitoxantrone
This is a "connection" page, showing publications Thomas Flaig has written about Mitoxantrone.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.126 |
|
|
|
-
Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glod? LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6.
Score: 0.309
-
Flaig TW, Su LJ, Harrison G, Agarwal R, Glod? LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 01; 120(9):2028-33.
Score: 0.291
-
Bowles DW, Flaig TW. Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review. Cancer Invest. 2006 Aug-Sep; 24(5):517-20.
Score: 0.276
-
Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504.
Score: 0.155
-
Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5.
Score: 0.096
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|